ACM
DNTH icon

Altium Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Altium Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,274
Closed -$1.95M – 138
2021
Q1 		$1.95M Buy
+10,274
New +$1.73M 0.54% 80

Other funds holding DNTH

TRV GP IV
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
Gilder Gagnon Howe & Co
Gilder Gagnon Howe & Co New York $9.7B AUM 55.7% 1-Year Est. Return
Casdin Capital
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Great Point Partners
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Altium Capital Management's DNTH Position: Q2 2021 in Review

Altium Capital Management sold out of Dianthus Therapeutics (DNTH) in Q2 2021, closing a stake of 10,274 shares — an estimated $1.95M sold.

Altium Capital Management first reported a position in DNTH in Q1 2021 and held it in 1 quarter. The position peaked at $1.95M in Q1 2021. 97 funds tracked by Wall St. Rank hold DNTH as of Q2 2021.

  • Altium Capital Management reported no remaining Dianthus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Altium Capital Management sold 10,274 Dianthus Therapeutics shares in Q2 2021, an estimated $1.95M.
  • Altium Capital Management first reported a position in Dianthus Therapeutics in Q1 2021 and held it in 1 quarter.
  • Altium Capital Management's Dianthus Therapeutics position peaked at $1.95M in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2021.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.